immunotherapy

0:47
Patient monitoring following CAR T-cell therapy
Erik Aerts
1:37
Patient education in CAR T-cell therapy
Monique Minnema
1:06
The role of nurses in apheresis during CAR T-cell therapy
Erik Aerts
2:56
The future landscape of CAR T-cell therapy
Elaine Vickers
1:58
The logistical challenges of CAR T-cell therapy
Monique Minnema
4:48
The quality control measures recommended within the JACIE model
Eoin McGrath
3:49
The limitations of immunotherapy with CAR T-cells
Elaine Vickers
0:48
HCP collaboration in CAR-T cell therapy
Erik Aerts
0:59
The clinical implementation of CAR T-cell therapy
Monique Minnema
1:29
Settings for CAR T-cell therapy
Erik Aerts
3:07
CAR T-cell therapy: cancer immunotherapy beyond checkpoint inhibitors
Elaine Vickers
0:59
Factors to consider by patients regarding CAR T-cell therapy
Monique Minnema
1:12
CAR T-cell therapy economics in the real world
Duane Schulthess
2:39
The patient registry for monitoring long term safety of novel therapies
Martina Schüßler-Lenz
1:16
Uptake of CAR T-cell therapy in Europe
Duane Schulthess
1:24
The JACIE model for centers administering CAR T-cell therapy
Eoin McGrath
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals © ®